BioSpace News Archive

The global Therapeutic Drug Monitoring market valued at USD 1,453.7 Million in 2020 and is expected to reach USD 2,429.1 Million by year 2030, at a CAGR of 6.6%.

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced plans to participate in the upcoming 15th Clinical Trials on Alzheimer’s Disease (CTAD) Task Force in San Francisco, California from November 29 to December 2, 2022.

Centene Corporation announced that it has appointed Monte Ford to the Centene Board of Directors, effective November 12th.

Travere Therapeutics, Inc. announced that on November 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 173,000 shares of its common stock to 12 new employees, consisting of inducement stock options to purchase an aggregate of 90,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 83,000 shares of its common stock.

Bioventus Inc., a global leader in innovations for active healing, announced the Company has filed a Form 12b-25, Notification of Late Filing for its Quarterly Report on Form 10-Q for the period ended October 1, 2022.

Pictor, a global leader in immunodiagnostics, announced that its PictArray™ SARS-CoV-2 IgG enzyme-linked immunosorbent assay antibody test will soon be available in New Zealand.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the Phase 3 SPOTLIGHT clinical trial evaluating the efficacy and safety of zolbetuximab in combination with mFOLFOX6 (a combination regimen that includes oxaliplatin, leucovorin and fluorouracil).

BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2022.

Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today the approval of the Investigational New Drug (IND) application by China National Medical Products Administration (NMPA) for the in-house developed oral PD-L1 small molecule inhibitor, ASC61, for the treatment of advanced solid tumors.

NuVasive, Inc. announced today that Chief Executive Officer Chris Barry will participate in the Piper Sandler 34th Annual Healthcare Conference in New York on Wednesday, November 30, 2022.